SEHK:1093Pharmaceuticals
Assessing CSPC Pharmaceutical Group (SEHK:1093) Valuation After New Obesity And Pain Drug Trial Clearances
CSPC Pharmaceutical Group (SEHK:1093) has drawn fresh attention after securing regulatory clearance to begin clinical trials for two long acting drug candidates targeting obesity, weight related conditions, and post operative pain.
See our latest analysis for CSPC Pharmaceutical Group.
The recent regulatory clearances arrive after a strong run, with CSPC Pharmaceutical Group’s 90 day share price return of 35.40% and 1 year total shareholder return of 118.26% pointing to building momentum...